Positions

Overview

  • Dr. Overton joined the UAB faculty in 2011 to assist in the development of the translational research program in the field of vaccinology and to establish a comprehensive hepatitis C program. He serves as the Co-Director of the AVRC and the Clinic Director for the 1917 Hepatitis Clinic. He is Board-certified in Medicine and Infectious Diseases and is licensed to practice in Alabama. His research interests focus on the chronic inflammation and long-term complications of chronic viral infections, specifically HIV and viral hepatitis, as well as understanding the underlying immune system with regards to vaccines and HIV infection. He has published numerous papers on many aspects of the complications of HIV infection. Specifically, he has evaluated vaccine responses among HIV-infected persons in an effort to better characterize the impact of this immunosuppressive state on the development of both humoral and cellular immune responses. He has conducted studies of hepatitis A, hepatitis B, HPV, HIV, anthrax, smallpox, zoster, and influenza vaccines.

    Dr. Overton’s clinical duties include seeing HIV-infected and chronic hepatitis patients in the outpatient setting as well as seeing solid organ and bone marrow transplant patients in the hospital. He has developed strong relationships with the UAB hepatology group as well as the bone marrow transplant unit and can readily identify potential study participants from these high risk populations. In addition, he has considerable experience in performing clinical trials, both randomized controlled trials and observational studies, assessing various parameters related to HIV, HCV, and vaccine responses. He has also served as the lead investigator on several trials within the AIDS Clinical Trial Group.
  • Selected Publications

    Chapter

    Year Title Altmetric
    2013 Infections of the immunocompromised patient.  704-709. 2013
    2012 Infections of the immunocompromised patient.  704-709. 2012
    2012 Prevention of hepatitis infection in HIV-Infected patients.  151-161. 2012

    Principal Investigator On

  • A-Z Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by SOCIAL & SCIENTIFIC SYSTEMS
  • A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"  awarded by Brigham and Women's Hospital
  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)  awarded by University of California, Los Angeles
  • A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV  awarded by Brigham and Women's Hospital
  • A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)  awarded by University of California, Los Angeles
  • ACTG Protocol Funds  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: TSG-Sci Comm] Sub award# 1560 G YB529  awarded by University of California, Los Angeles
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital
  • Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee  awarded by Brigham and Women's Hospital
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults - Fixed Price  awarded by Indiana University
  • Ancillary Studies of NAFLD and NASH in HIV infected Adults - Zydus Clinical Trial Aim 4  awarded by Indiana University
  • Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants  awarded by Brigham and Women's Hospital
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314  awarded by Brigham and Women's Hospital
  • Effect of Pitavastatin on Kidney Function in HIV-infected Persons  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Evaluating Nonavalent HPV Vaccine Immunogenicity among Adult Renal Transplant Recipients (Fixed Price Agreement)  awarded by Northwestern University
  • Evaluating Nonavalent HPV vaccine Immunogenicity among Adult Renal Transplant Recipients  awarded by Northwestern University
  • HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (ViiV)  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Personal Protective Equipment- HPTN Studies  awarded by FAMILY HEALTH INTERNATIONAL
  • HPTN Unanticipated Clinical Trials Costs  awarded by FAMILY HEALTH INTERNATIONAL
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients  awarded by VANDERBILT UNIVERSITY
  • Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support  awarded by University of California, Los Angeles
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)  awarded by University of California, Los Angeles
  • Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)  awarded by University of Colorado
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GlaxoSmithKline
  • Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332) and ACTG A5333s The Mechanistic Substudy of REPRIEVE  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • UAB Center for AIDS Research - The Detrimental Nexus of HCV and HIV Infection on Bioenergetics and Immune Function  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Investigator On

  • (CSSC-001) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control( SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19 and (CSSC-004) Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma)  awarded by Johns Hopkins University
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION
  • Amplifying Our Voice: Understanding HIV PrEP Promotional Messaging to Create Authentic PrEP Content by Men Who Have Sex with Men in the Deep South  awarded by National Institute of Mental Health/NIH/DHHS
  • COMPLETED - SPORE in Cervical Cancer - Project 3  awarded by Johns Hopkins University
  • Center For AIDS Research - Social Determinants of Health Disparities and Multiple Co-Morbidities among Men and Women Living with HIV  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Clincial Research Site Activities for the LTE to HVTN 117/HPX2004  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3002 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3003 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 3006 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • CoVPN 5001 (Acute Immune Responses to SARS-CoV-2 Infection) Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplement to Stimulate Research in HIV/AIDS Cancer Research  awarded by National Cancer Institute/NIH/DHHS
  • Convalescent Plasma Randomized Clinical Trials for SARS-CoV-2 Prophylaxis and Early COVID-19 Treatment are Foundational for Subsequent Hyperimmune Globulin and Vaccines  awarded by Johns Hopkins University
  • Determining the Structural- and Functional-Level Effects of Diet-Specific Interventions on the Gut Microbiota of a Racially Diverse Sample of Southern United States Adults  awarded by National Cancer Institute/NIH/DHHS
  • Establishing Normative Cognitive Data for UAB Medical Professionals  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation  awarded by Johns Hopkins University
  • HPTN 078: Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States  awarded by FAMILY HEALTH INTERNATIONAL
  • HPX3002/HVTN 706 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 14  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 405/HPTN 1901 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 505 Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 703/HPTN 081 Site Readiness  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 704/HPTN 085 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN 704/HPTN 085 Protocol Funding (PF) - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (Pf): Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 13  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding Year 16  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Implementation Funds  awarded by Hutchinson (Fred) Cancer Research Center
  • Hope in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation  awarded by Johns Hopkins University
  • Impact of CCR5 Blockade in HIV+Kidney Transplant Recipients  awarded by University of California, San Francisco
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Interdisciplinary Training in Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) COVID 19 SUPPLEMENT  awarded by Emory University
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 118/HPX2003 - Birmingham Clinical Research Site  awarded by Hutchinson (Fred) Cancer Research Center
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Population Genetics Analysis Program: Immunity to Vaccines/Infections II  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by HEMISPHERX BIOPHARMA, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC
  • Private Grant  awarded by CEPHEID
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by JANSSEN R&D IRELAND
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by SANOFI PASTEUR LIMITED
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Regional AIDS Education and Training Centers-Base  awarded by Emory University
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University
  • Screening, Evaluation, and Treatment of Anal Intraepithelial Neoplasia  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • The Guts of HIV: Innate Immune Dysregulation as a Central Mechanism of Gastrointestinal and Liver Disease in HIV-1-Infected Individuals  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research (CFAR)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Clinical Core C  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Core C - Clinical Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - Lipidomic Profiling in HIV Patients Newly Initiating Antiretroviral Treatment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Microbiome, Diet, and Incomplete CD4 Recovery on Antiretroviral Therapy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Institutional Career Development Program in HIV-Related Heart, Lung, Blood and Research  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB-MISS WIHS Cohort  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER ^
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • Barnes-Jewish West County Hospital, Postdoctoral Fellowship
  • Full Name

  • Edgar Overton